HK Stock Market Move | XTALPI (02228) rose over 8% in the closing session, the world's first pan-TEAD inhibitor made its debut at the 2026 Guangdong Artificial Intelligence Conference.

At the close of trading, XTALPI (02228) rose more than 8%, up 8.14% to HK$9.17 with a trading volume of HK$537 million. On the news front, on April 27, Ma Jian, CEO of Crystal Technology, announced at the 2026 Guangdong Province Artificial Intelligence Application Docking Conference that the broad TEAD inhibitor SIGX2649 developed by Hegesys Bioscience, a company incubated by its AI autonomous experimental platform, has completed preclinical studies and will simultaneously submit an IND application to regulatory agencies in China and the United States. The related results will also be unveiled at the 2026 American Association for Cancer Research (AACR) Annual Meeting. It is reported that SIGX2649 is a potential first-in-class/best-in-class broad TEAD inhibitor with a wide drug market in the field of solid tumor therapy. As a core target of the HIPPO pathway, preclinical data shows that SIGX2649 can effectively inhibit four TEAD subtypes, with stronger anti-tumor activity, lower kidney toxicity, and outstanding potential for combination therapy. There are currently no drugs on the market with the same target.